BioSpace News Archive

Lineage Cell Therapeutics, Inc. today announced that full results from a Phase 1/2a clinical study of RG6501 will be presented at the 2022 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2022), to be held May 1 – 4, 2022 at the Colorado Convention Center in Denver, CO.

Masimo announced a major expansion of Masimo Patient SafetyNet™, its premier hospital remote patient monitoring and clinician notification platform, with the addition of secure telehealth capabilities – making an already powerful solution even more versatile and comprehensive.

Elektrofi & IPA announced they are entering into a collaboration to explore a high-concentration formulation of IPA’s COVID-19 antibody cocktail, PolyTope® TATX-03.

Avinger, Inc. today announced that the Company will effect a 1-for-20 reverse stock split of the Company’s common stock, which will be effective at 5:00 p.m. Eastern time on Monday, March 14, 2022.

StageZero Life Sciences, Ltd. announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe.

Solid Biosciences Inc. today provided an update from the ongoing IGNITE DMD Phase I/II clinical trial, as well as a business and financial update.

Evogene Ltd. today announced that it will be attending the Jefferies Virtual Synthetic Biology Week which is taking place between March 21-25, 2022.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2021 and provided a business update.

Applied DNA Sciences, Inc. today announced that the two companies have executed a non-binding letter of intent (“LOI”) that outlines the terms of a collaborative research agreement (the “Definitive Agreement”) to investigate the feasibility of utilizing the Company’s LinearDNATM platform.

Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura™) for the treatment of vitiligo.